scout
Opinion|Videos|March 11, 2025

Sequencing Multiple Lines of Therapy in Metastatic RCC

An expert discusses using sequence therapies based on disease progression, patient factors, and resistance mechanisms. After a first-line tyrosine kinase inhibitor plus immune checkpoint inhibitor (TKI +  ICI) regimen, preferred subsequent-line options include alternative TKIs, chemotherapy, or combination strategies, tailored to patient response and tolerability.

Episodes in this series

Video content above is prompted by the following:

  • How are you sequencing these agents through multiple lines of therapy?
  • Thinking beyond the patient case just reviewed, please discuss your preferred subsequent line after a first-line TKI + ICI regimen.
  • Would you have followed the sequence of therapies used for the patient described in this case?

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!

Related Content

Latest CME

42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow
Multimedia

42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow

Benjamin P. Levy, MD; John O. Mascarenhas, MD; Tiffany A. Traina, MD, FASCO; Cathy Eng, MD, FACP, FASCO; John P. Leonard, MD

View more
Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society
Video

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Marla D. Lipsyc-Sharf, MD; Ashley Frith, MD

View more
The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference
Video

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

Hope S. Rugo, MD, FASCO; Naoto T. Ueno, MD, PhD

View more
43rd Annual Miami Breast Cancer Conference®
In-Person Event

43rd Annual Miami Breast Cancer Conference®

March 5-8, 2026

Register now!
Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer
Video

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Joyce O’Shaughnessy, MD; William J. Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH

View more
Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention
Video

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Patrick I. Borgen, MD; Joshua Feinberg, MD; Gary Schwartz, MD, FASA

View more
Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment
Multimedia

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Patrick I. Borgen, MD; E. Shelley Hwang, MD, MPH; Mark E. Robson, MD

View more
Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care
Multimedia

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Hope S. Rugo, MD, FASCO; Sara Hurvitz, MD, FACP; Jennifer Litton, MD, MHCM; Heather McArthur, MD, MPH

View more
Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment
Multimedia

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Heather McArthur, MD, MPH; Komal Jhaveri, MD, FACP; Sara Tolaney, MD, MPH; Seth A. Wander, MD, PhD

View more
Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer
Multimedia

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Joyce O’Shaughnessy, MD; William Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH; Eleni Anastasia Tousimis, MD, MBA, FACS

View more
Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer
Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

View more
Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation
Multimedia

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Rita Nanda, MD; William Gradishar, MD, FASCO, FACP; Komal Jhaveri, MD, FACP; Kevin Kalinsky, MD, MS

View more
Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®
Multimedia

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

View more
Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer
Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

View more
Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates
Video

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

View more